{
	"QALYs in Cost-Effectiveness Analysis: An Overview for Cardiologists":"https://eprints.lse.ac.uk/63798/1/__lse.ac.uk_storage_LIBRARY_Secondary_libfile_shared_repository_Content_Wouters,%20O_QALYs%20cost-effectiveness_Wouters_QALYs%20cost-effectiveness_2015.pdf",
	"NICE Health Economic Report on Cost-Effectiveness of Antihypertensive Drugs":"https://www.nice.org.uk/Media/Default/standards-and-indicators/qof%20indicator%20key%20documents/NM53%20cost%20effectiveness%20analysis.pdf",
	"Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8304800/",
	"Cost-benefit Effectiveness of Angiotensin-II Receptor Blockers in Hypertension":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5553545/",
	"Cost Effectiveness of Antihypertensive Drugs and Treatment Guidelines":"https://pubmed.ncbi.nlm.nih.gov/34075437/",
	"Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5523762/",
	"Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets":"https://database.inahta.org/article/32587",
	"Low Density Lipoprotein Cholesterol (LDL-C) Lowering in a Population Represented in a Meta-Analysis of Major Randomized Trials is Associated with a Positive Health-Economic Benefit":"https://www.ahajournals.org/doi/10.1161/circ.124.suppl_21.A10485",
	"Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics":"https://pubmed.ncbi.nlm.nih.gov/10819699/",
	"The Cost-Effectiveness of Hyperlipidemia Medication in Low- and Middle-Income Countries":"https://globalheartjournal.com/articles/10.5334/gh.1097",
	"Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7385861/",
	"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60367-5/fulltext",
	"Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors":"https://pmc.ncbi.nlm.nih.gov/articles/PMC434521/"
}